- All sections
- C - Chemistry; metallurgy
- C12N - Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media
- C12N 9/22 - Ribonucleases
Patent holdings for IPC class C12N 9/22
Total number of patents in this class: 10064
10-year publication summary
241
|
351
|
485
|
724
|
915
|
1164
|
1258
|
1394
|
1551
|
554
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
The Regents of the University of California | 18943 |
453 |
The Broad Institute, Inc. | 1584 |
427 |
President and Fellows of Harvard College | 5792 |
417 |
Massachusetts Institute of Technology | 9795 |
403 |
Sangamo Therapeutics, Inc. | 437 |
188 |
Cellectis | 397 |
146 |
Inscripta, Inc., FORMERLY Muse Biotechnology, Inc. | 300 |
144 |
CRISPR Therapeutics AG | 361 |
126 |
The General Hospital Corporation | 4517 |
125 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
122 |
Editas Medicine, Inc. | 225 |
122 |
Arbor Biotechnologies Inc. | 144 |
117 |
Pioneer Hi-Bred International, Inc. | 6264 |
101 |
Novozymes A/S | 3314 |
97 |
Beam Therapeutics Inc. | 176 |
96 |
Pairwise Plants Services, Inc. | 185 |
92 |
Precision Biosciences, Inc. | 167 |
89 |
University of Vienna | 109 |
85 |
Duke University | 2872 |
82 |
University of Massachusetts | 2130 |
82 |
Other owners | 6550 |